Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

99
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
99
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

19.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
19.6K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

65
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

57
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
57
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

79
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
79
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

98
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
98

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-omics profiles of sex hormone-binding globulin are associated with subclinical atherosclerosis in men with HIV.

Genome medicine·2026
Same author

Exploring the association between common genetic deletions and aging: insights from the Canadian Longitudinal Study on Aging.

GeroScience·2026
Same author

Microbial reactivation of host androgens directs enteric neuronal regulation of gut motility.

Nature neuroscience·2026
Same author

Severity-guided management of esophageal perforation: a retrospective cohort study supporting a pragmatic treatment algorithm.

World journal of emergency surgery : WJES·2026
Same author

General anesthesia with intubation and emergency endoscopy outcomes in patients with upper gastrointestinal bleeding: an inverse probability of treatment weighting study.

Anaesthesia, critical care & pain medicine·2026
Same author

LC-MS/MS-based simultaneous high-sensitivity quantification of clinically relevant high-potency androgens and estrogens in plasma and serum.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2026

Related Experiment Video

Updated: Mar 19, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.9K

Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.

Jean-Nicolas Cornu1,2, Etienne Audet-Walsh3, Sarah Drouin4,5

  • 1Academic Department of Urology, Hopital Tenon, AP-HP, UPMC University Paris 06, Paris, 75020, France. jeannicolas.cornu@gmail.com.

World Journal of Urology
|June 10, 2016
PubMed
Summary
This summary is machine-generated.

Genetic variants in steroid hormone metabolism, particularly estrogen pathways, are linked to prostate volume. These findings suggest a role for estrogen signaling in benign prostatic hyperplasia (BPH) development.

Keywords:
Prostate weightProstatectomySingle nucleotide polymorphismsSteroid pathway

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

14.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.9K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.3K
Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis
07:42

Laser-capture Microdissection of Human Prostatic Epithelium for RNA Analysis

Published on: November 26, 2015

14.0K

Area of Science:

  • Urology
  • Genetics
  • Endocrinology

Background:

  • Preliminary studies suggest a genetic link to benign prostatic hyperplasia (BPH).
  • The steroidogenesis pathway is a potential area of interest for BPH etiology.

Purpose of the Study:

  • To investigate the association between single nucleotide polymorphisms (SNPs) in the steroid pathway and prostate volume.
  • To identify specific genetic variants influencing prostate size in a cohort undergoing radical prostatectomy.

Main Methods:

  • Analyzed clinical and pathological data from 611 Caucasian men.
  • Genotyped 90 SNPs related to the steroid pathway.
  • Used analysis of covariance and multivariable models to assess correlations between genotypes and prostate weight, adjusting for age and tumor stage.

Main Results:

  • Seven SNPs in or near steroid metabolism genes (HSD17B2, ESR2, SULT2B1, NQO1, ESR1, GSTP1, CYP19A1) were significantly associated with prostate volume.
  • Four SNPs maintained independent association after multivariate analysis.
  • The strength of association for some SNPs was comparable to that of age.

Conclusions:

  • Estrogen biotransformation and signaling pathways appear to play a role in the pathophysiology of BPH.
  • Variants in ESR1, ESR2, HSD17B2, and CYP19A1 genes show the strongest association with prostate volume, highlighting the potential impact of estrogen signaling.